The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population.

MLA

Srinivasan, Mythili, et al. “The Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II Clinical Trial: Rationale, Study Design, Methods, and Characteristics of Study Population.” Contemporary Clinical Trials Communications, vol. 22, June 2021, p. 100798. EBSCOhost, https://doi.org/10.1016/j.conctc.2021.100798.

APA

Srinivasan, M., Bacharier, L. B., Goss, C. W., Zhou, Y., Boomer, J., Bram, S., Burgdorf, D., Burnham, C.-A., Casper, T., Castro, M., Coverstone, A., Haslam, M., Kanchongkittiphon, W., Kuklinski, C., Lian, Q., Schechtman, K., Storch, G. A., True, K., Wallace, M. A., … Beigelman, A. (2021). The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population. Contemporary Clinical Trials Communications, 22, 100798. https://doi.org/10.1016/j.conctc.2021.100798

Chicago

Srinivasan, Mythili, Leonard B Bacharier, Charles W Goss, Yanjiao Zhou, Jonathan Boomer, Sarah Bram, Dana Burgdorf, et al. 2021. “The Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II Clinical Trial: Rationale, Study Design, Methods, and Characteristics of Study Population.” Contemporary Clinical Trials Communications 22 (June): 100798. doi:10.1016/j.conctc.2021.100798.